FDA-cleared profile

iQ-solutions

Sydney Neuroimaging Analysis Centre Pty Ltd · MRI · FDA-cleared (510(k))

Authorized purpose: Automatically annotate, visualize, and quantify segmentable brain structures from brain MRI at one time point or longitudinally; longitudinal analysis is limited to the same patient's scans from the same scanner with consistent protocol and contrast at two time points.

Clinical role
Post-acquisition MRI segmentation, annotation, visualization, volume analysis, and longitudinal change analysis, with the user reviewing the returned reports and masks.
Images and patients
MRI · Brain
Key limitation
Keep in mind: The results are not a diagnostic tool and interpretation remains the responsibility of qualified radiologists or physicians. Longitudinal analysis requires the same scanner, consistent acquisition protocol, and consistent contrast at two time points; cross-sectional and longitudinal results cannot be compared. The device processes brain MRI only, not the predicate's NCCT input, and generated overlays are watermarked for non-diagnostic use.

Overview status: Source-reviewed overview

Report a correction
Clinical details Purpose, workflow fit, evidence, and safety record

Workflow navigation pilot

Workflow role has not yet been reviewed for this navigation pilot.

A tag identifies a documented role; it does not establish compatibility or local acceptance. Methods and sources

  • What does this software do?Authorized purpose: Automatically annotate, visualize, and quantify segmentable brain structures from brain MRI at one time point or longitudinally; longitudinal analysis is limited to the same patient's scans from the same scanner with consistent protocol and contrast at two time points.
  • Which images or clinical context are in scope?Modality: MRI Anatomy or clinical context: Brain Input: DICOM brain MRI including pre-contrast T1-weighted scans from single or multiple time points, FLAIR scans from single or multiple time points, and post-contrast T1-weighted scans from a single time point.
  • Who uses it?Intended users: Trained professionals in hospitals, imaging centers, and image-processing labs, including qualified radiologists and physicians.
  • What does the software produce?Output: PDF quantitative reports, annotated DICOM images and masks with colored overlays, and dynamic webpage reports containing brain and substructure volumes or changes, asymmetry measures, white-matter-hyperintensity volumes, contrast-enhancing hyperintensity volumes, and healthy-cohort comparisons.
  • What is its most important limitation?Key limitation: The results are not a diagnostic tool and interpretation remains the responsibility of qualified radiologists or physicians. Longitudinal analysis requires the same scanner, consistent acquisition protocol, and consistent contrast at two time points; cross-sectional and longitudinal results cannot be compared. The device processes brain MRI only, not the predicate's NCCT input, and generated overlays are watermarked for non-diagnostic use.

Clinical takeaway. Clinical role: Automatically annotate, visualize, and quantify segmentable brain structures from brain MRI at one time point or longitudinally; longitudinal analysis is limited to the same patient's scans from the same scanner with consistent protocol and contrast at two time points.

Evidence takeaway. Evidence from the reviewed source record: FDA K231929 reports non-clinical bench verification after development on private and public MRI datasets, with module-specific results including sequence-classification accuracy 100%, brain-extraction Dice 0.982, white-matter-hyperintensity Dice 0.789, contrast-enhancing-lesion Dice 0.790, brain-tissue Dice 0.972, brain-volume-change R2 0.869, WMH-activity R2 0.833, cortical/subcortical segmentation R2 0.833, and substructure-volume-change STD 0.0102. The summary includes an 81-patient comprehensive test set and a 120-scan test-retest dataset, and states that no clinical tests were conducted.

Evidence context

Evidence context not reviewed for this FDA record.

Public-label constraints

Label constraints have not been reviewed for this exact FDA record. Unknown is not all ages or evidence of unsuitability.

Public-label constraints, not patient-level eligibility or a medical recommendation. Training and evaluation populations are separate. Read the original labeling and confirm the exact release and protocol.

Purpose
Automatically annotate, visualize, and quantify segmentable brain structures from brain MRI at one time point or longitudinally; longitudinal analysis is limited to the same patient's scans from the same scanner with consistent protocol and contrast at two time points.
  • Exact FDA submission
  • Checked 2026-09-08
Workflow role
Post-acquisition MRI segmentation, annotation, visualization, volume analysis, and longitudinal change analysis, with the user reviewing the returned reports and masks.
  • Exact FDA submission
  • Checked 2026-09-08
Required input
DICOM brain MRI including pre-contrast T1-weighted scans from single or multiple time points, FLAIR scans from single or multiple time points, and post-contrast T1-weighted scans from a single time point.
  • Exact FDA submission
  • Checked 2026-09-08
Output and clinician action
PDF quantitative reports, annotated DICOM images and masks with colored overlays, and dynamic webpage reports containing brain and substructure volumes or changes, asymmetry measures, white-matter-hyperintensity volumes, contrast-enhancing hyperintensity volumes, and healthy-cohort comparisons.
  • Exact FDA submission
  • Checked 2026-09-08
Care setting
Hospitals, imaging centers, or image-processing laboratories.
  • Exact FDA submission
  • Checked 2026-09-08
Intended users
Trained professionals in hospitals, imaging centers, and image-processing labs, including qualified radiologists and physicians.
  • Exact FDA submission
  • Checked 2026-09-08
Limitations
The results are not a diagnostic tool and interpretation remains the responsibility of qualified radiologists or physicians. Longitudinal analysis requires the same scanner, consistent acquisition protocol, and consistent contrast at two time points; cross-sectional and longitudinal results cannot be compared. The device processes brain MRI only, not the predicate's NCCT input, and generated overlays are watermarked for non-diagnostic use.
  • Exact FDA submission
  • Checked 2026-09-08
Evidence summary
FDA K231929 reports non-clinical bench verification after development on private and public MRI datasets, with module-specific results including sequence-classification accuracy 100%, brain-extraction Dice 0.982, white-matter-hyperintensity Dice 0.789, contrast-enhancing-lesion Dice 0.790, brain-tissue Dice 0.972, brain-volume-change R2 0.869, WMH-activity R2 0.833, cortical/subcortical segmentation R2 0.833, and substructure-volume-change STD 0.0102. The summary includes an 81-patient comprehensive test set and a 120-scan test-retest dataset, and states that no clinical tests were conducted.
  • Exact FDA submission
  • Checked 2026-09-08

Evidence

Performance evidence

Metrics are shown only when they are tied to a source, endpoint, population, and tested product version. Candidate literature without exact product and version linkage is not shown as product evidence.

Evidence summary
FDA K231929 reports non-clinical bench verification after development on private and public MRI datasets, with module-specific results including sequence-classification accuracy 100%, brain-extraction Dice 0.982, white-matter-hyperintensity Dice 0.789, contrast-enhancing-lesion Dice 0.790, brain-tissue Dice 0.972, brain-volume-change R2 0.869, WMH-activity R2 0.833, cortical/subcortical segmentation R2 0.833, and substructure-volume-change STD 0.0102. The summary includes an 81-patient comprehensive test set and a 120-scan test-retest dataset, and states that no clinical tests were conducted.
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-08
Reported sensitivity
Research pending
  • Needs research
  • Exact FDA submission
  • Checked 2026-08-31

This field has not been curated yet.

Reported specificity
Research pending
  • Needs research
  • Exact FDA submission
  • Checked 2026-08-31

This field has not been curated yet.

No contextualized exact-version metric has completed evidence review. Regulatory-document values, when available, are shown above with their limitations.

iQ-solutions regulatory performance study summary

  • DesignStand-Alone Performance
  • PopulationPopulation described in the exact-submission ACR model card
  • Scopeexact submission
  • Tested versionExact product version not reported; regulatory study summarized for FDA submission K231929
  • Samplen=1769
  • IndependenceIndependence not established

K231929

ACR AI Central summarizes the regulatory study; consult the exact FDA materials before comparative use.

Safety and lifecycle

Postmarket record

Recall and adverse-event records are shown only after product matching. Adverse-event reports do not establish incidence or causality.

Postmarket safety review
The exact-identifier FDA recall query returned no native recall record for K231929. This limited result does not establish absence of recalls or other safety information and does not cover later versions, family records, MAUDE reports, corrections, or field notices.
  • Public source
  • Exact FDA submission
  • Checked 2026-09-08
Pricing & contracts Public price, contract terms, and reimbursement

Price not public here; enter your quote

Not verified: Pricing information is recorded but not verified against a resolving source.

Reimbursement

IT implementation Deployment, interfaces, data handling, and support

System and version relationships

Match the AI release, system build, configuration and region. Source documentation does not establish acceptance of an installed system.

No specific system/version pairing has completed review for this FDA record. A broad DICOM or product-family statement does not establish a named viewer build's support.

Review Merge, Visage, Sectra, AGFA and IntelePACS context

Integration chain: evidence at each hop

Public source context, not tested interoperability. Each hop needs its own release/configuration evidence. Missing or unavailable routes are not documented incompatibility. All local tests are planned, not passed; no installed-system acceptance is recorded.

Acquisition/source → routing → AI processing → returned objects → viewer/worklist/report → support owner

No specific route context has been source-reviewed for this record. Obtain both endpoint builds and documents; this is not a finding of incompatibility.

  1. Acquisition/source

    Source context, not route validation: DICOM brain MRI including pre-contrast T1-weighted scans from single or multiple time points, FLAIR scans from single or multiple time points, and post-contrast T1-weighted scans from a single time point.

    Scope: Exact FDA submission.

    Confirm scanner/model, protocol, series completeness and both software builds.

    Field checked 2026-09-08 · FDA K231929: iQ-solutions

  2. Routing

    Source context, not route validation: MRI scans are transmitted from the user's PACS through a medical-image routing or integration platform, and PDF reports plus DICOM results return to PACS or another user-specified radiology software system or database. Specific interfaces, versions, and local compatibility require confirmation.

    Scope: Exact FDA submission.

    Name gateways, destinations, transfer rules and failure visibility; a DICOM statement does not prove a route.

    Field checked 2026-09-08 · FDA K231929: iQ-solutions

  3. AI processing

    Source context, not route validation: The exact FDA package describes iQ-solutions as software that operates on off-the-shelf hardware from multiple vendors. Current hosting, data flow, and commercial configuration require vendor confirmation.

    Scope: Exact FDA submission. Packet wording: "Operates on off-the-shelf hardware (multiple vendors)". Read from the exact FDA decision document on 2026-11-14; this is the release-level description, not current commercial configuration.

    Confirm processing location, queue ownership, exclusions and exact AI build.

    Field checked 2026-11-14 · FDA K231929: iQ-solutions

  4. Returned objects

    Source context, not route validation: PDF quantitative reports, annotated DICOM images and masks with colored overlays, and dynamic webpage reports containing brain and substructure volumes or changes, asymmetry measures, white-matter-hyperintensity volumes, contrast-enhancing hyperintensity volumes, and healthy-cohort comparisons.

    Scope: Exact FDA submission.

    Confirm object classes, units, references and whether findings, overlays or measurements reach their intended destination.

    Field checked 2026-09-08 · FDA K231929: iQ-solutions

  5. Viewer/worklist/report

    Unresolved route: PDF quantitative reports, annotated DICOM images and masks with colored overlays, and dynamic webpage reports containing brain and substructure volumes or changes, asymmetry measures, white-matter-hyperintensity volumes, contrast-enhancing hyperintensity volumes, and healthy-cohort comparisons.

    Scope: Exact FDA submission.

    Confirm the named viewer/worklist/report build, display behavior and report transfer. Output support alone does not establish this endpoint. The displayed source describes output, not validated end-to-end delivery.

    Field checked 2026-09-08 · FDA K231929: iQ-solutions

  6. Support owner

    Unresolved route: Not established for the exact route.

    Scope: Scope not established.

    Name the local, platform and AI supplier support owners and escalation path.

Planned local route tests

No tests below have been performed or accepted.

  1. Patient/study identity (planned). Use approved non-patient test data to verify identifiers, accession and result-to-study linkage at every hop.
  2. Study completeness (planned). Test missing views/series, partial transfer, late arrivals, priors and unsupported acquisition inputs; confirm explicit refusal or fallback.
  3. Ordering and duplicates (planned). Send out-of-order, repeated and corrected studies; verify worklist order, deduplication and no misleading stale results.
  4. Report transfer (planned). Verify output object types, annotations, units, report content, destination and availability of original images.
  5. Access (planned). Verify authorized roles, audit trail, denied access and support ownership at each destination.
  6. Latency and failures (planned). Agree a workload and turnaround target; test queues, timeouts, missing results and fallback reading.
  7. Updates and rollback (planned). Define version change control, revalidation triggers, stop-use criteria and a tested rollback route.

Local implementation checklist

Agree the evidence and acceptance owner with your team and suppliers. Checkmarks apply to this page only and are not acceptance receipts.

Open the printable evaluation checklist

Deployment
The exact FDA package describes iQ-solutions as software that operates on off-the-shelf hardware from multiple vendors. Current hosting, data flow, and commercial configuration require vendor confirmation.
  • Exact FDA submission
  • Checked 2026-11-14

Packet wording: "Operates on off-the-shelf hardware (multiple vendors)". Read from the exact FDA decision document on 2026-11-14; this is the release-level description, not current commercial configuration.

Integration
MRI scans are transmitted from the user's PACS through a medical-image routing or integration platform, and PDF reports plus DICOM results return to PACS or another user-specified radiology software system or database. Specific interfaces, versions, and local compatibility require confirmation.
  • Exact FDA submission
  • Checked 2026-09-08

Input or output interoperability

DICOM is explicitly referenced in the described input, output, or workflow.

exact submission · checked 2026-09-01

The model card does not establish every supported DICOM object, transfer method, or local interface.

ACR exact-submission catalog context

ACR AI Central provides an exact-submission model card for iQ-solutions; FDA labeling remains controlling for clinical use, limitations, and performance.

exact submission · checked 2026-09-08
Sources & review details FDA identity, research record, source ledger, and history

Regulatory identity

FDA record and catalog context

The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.

FDA submission
K231929
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
Modality
MRI
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-08
Anatomy
Brain
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-08
Clearance type
510(k)
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
Decision date
2023-12-18
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
FDA status
FDA-cleared
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31

Research record

What has been checked

This audit distinguishes completed source review from fields that have not yet been researched.

Exact FDA record reviewedStatus
2026-09-20Last searched
22Fields reviewed
9Source classes checked
0Screened PubMed leads
0Screened trial leads
0Unreviewed FDA recall leads

The refreshed discovery snapshot contains no PubMed or ClinicalTrials.gov candidates; no external evidence was promoted. The current discovery snapshot contains 0 PubMed and 0 ClinicalTrials.gov candidate records; its dated, count-matched human screening remains current. Unlinked candidates remain quarantined. Native FDA recall identifiers produced 0 postmarket candidate records; 0 have been reviewed (0 published, 0 rejected) and 0 remain unreviewed.

Candidate leads were screened against the exact product and tested version. Unlinked records remain quarantined.

Source classes: fda ai list, fda decision summary, acr ai central product, fda device recall, literature index, trial registry, pubmed, clinical trials, openfda device recall

Field review details

Recorded state, verification date, notes and sources for fields without a publishable value. Conflicting records stay explicitly unsettled here; no plain settled value is shown for them.

  • Public pricing: Not verified - checked 2026-09-08 - Exact FDA submission

    No public price or quote for the exact K231929 configuration was established in this review.

  • Pricing model: Not yet reviewed
  • Setup and integration fees: Not yet reviewed
  • Recurring fees: Not yet reviewed
  • Minimum commitment: Not yet reviewed
  • Contract duration: Not yet reviewed
  • Renewal terms: Not yet reviewed
  • Cancellation terms: Not yet reviewed
  • Support and service terms: Not yet reviewed
  • Trial or pilot terms: Not yet reviewed
  • Reimbursement: Not publicly available - checked 2026-09-08 - Exact FDA submission

    No exact-product payer policy, coding instruction, or payment determination was established; eligibility must be evaluated by payer, site of service, and use case.

  • Data hosting location: Not yet reviewed
  • Data retention: Not yet reviewed
  • Documented data use: Not yet reviewed
  • Hardware requirements: Not yet reviewed
  • Network requirements: Not yet reviewed
  • Identity and access: Not yet reviewed
  • Security: Not verified - checked 2026-09-08 - Exact FDA submission

    Exact-release security controls, data retention, hosting boundaries, and scoped assurance documentation require vendor confirmation.

  • Installation timeline: Not yet reviewed
  • Training: Not verified - checked 2026-09-08 - Exact FDA submission

    Current training prerequisites, competency checks, and support commitments for the exact configuration require vendor confirmation.

  • Monitoring: Not verified - checked 2026-09-08 - Exact FDA submission

    Current drift, quality, uptime, alert, escalation, and incident-response commitments for the exact configuration require vendor confirmation.

7 sources - 3 history items

Source ledger

  1. FDA K231929: iQ-solutions

    U.S. Food and Drug Administration - Published 2023-12-18 - Accessed 2026-09-08

    Scope: identity, clinicalUse, modality, anatomy, workflow, evidence, implementation, deployment

  2. Artificial Intelligence-Enabled Medical Devices

    U.S. Food and Drug Administration - Accessed 2026-08-31

    Scope: regulatoryIdentity, modalityContext

  3. iQ-solutions model card (K231929)

    American College of Radiology - Published 2026-08-17 - Accessed 2026-09-01

    Scope: intendedUsers, output, evidenceSummary, integration, anatomy, evidenceStudies, implementationCapabilities

  4. PubMed biomedical literature index

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery

  5. ClinicalTrials.gov study registry

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery, studyStatus

  6. openFDA Device Recall API

    U.S. Food and Drug Administration - Accessed 2026-09-02

    Scope: recallDiscovery, nativeSubmissionMatching

  7. openFDA exact recall query for K231929

    U.S. Food and Drug Administration - Accessed 2026-09-08

    Scope: postmarketSafety

Research history

  1. K231929 FDA decision

    Regulatory record

    510(k)

  2. Source-review record updated

    Research record

    fda record reviewed

  3. Reader overview source-reviewed

    Editorial review

    Source-reviewed editorial overlay

Alternatives

Related tools to compare

FDA-cleared K261405

ANDI 2.2

Imeka Solutions, Inc.

Authorized purpose: ANDI 2.2 processes brain MR images for atlas-assisted visualization, segmentation and volumetric quantification, presenting adjunctive DICOM-readable information for trained medical professionals; it does not predict, diagnose or interpret brain health.

Modality
MRI
Anatomy
Brain
Decision
2026-05-28
FDA-cleared K260032

Morph

BeauBrain Healthcare, Inc.

Authorized purpose: Morph automatically labels, visualizes, and volumetrically quantifies segmentable brain structures from MR images and may compare measurements with reference percentile data; it is adjunctive and not the sole basis for final decisions.

Modality
MRI
Anatomy
Brain
Decision
2026-05-13
FDA-cleared K253057

AI-Rad Companion Brain MR

Siemens Healthcare GmbH

Authorized purpose: Brain MRI morphometry and white matter hyperintensity quantification, including normative comparison and longitudinal change assessment for clinician review.

Modality
MRI
Anatomy
Brain
Decision
2026-01-22
FDA-cleared K252298

ANDI 2.0

Imeka Solutions, Inc.

Authorized purpose: Adjunctive quantitative brain MRI analysis that compares patient measures with normative and longitudinal references; a physician reviews all results and makes the clinical decision.

Modality
MRI
Anatomy
Brain
Decision
2025-10-22

Correct this exact record

Copy this public context and add the field, proposed wording and original source before sending. Nothing here is submitted automatically. Form-specific prefill has not been verified.

Open existing correction destination

Permission to display a submission is not evidence verification. A submission enters editorial review; it does not approve a public change. Form availability, data entry, receipt, review and publication are separate steps. Data entry and receipt remain unverified.

Accepted repository change history

No entry has been added to this scoped change history for this record. This is not proof that the record never changed.

Correction policy and limits · Public repository change history